nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Today, however, we will be daydreaming about a week-long respite. Yes, the time has come to disappear for a few days, although a colleague or two will assume Pharmalittle duties in our absence. And what about you? Any sojourns planned? This is a lovely time to enjoy the great outdoors or take an excursion. Well, whatever you do, have a grand time. But, be safe. See you all soon …

The first new drug for amyotrophic lateral sclerosis, or ALS, in 22 years was approved by U.S. regulators this week, causing excitement but also concerns, ABC News reports. Some physicians worry about the cost for Radicava — about $146,000 per year — as well as misconceptions about how effective the drug will be at fighting the degenerative condition  and that numerous infusions mean many such trips for patients with reduced mobility.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy